Peanut Allergy Treatment Market Report 2026

The peanut allergy treatment market size has grown rapidly in recent years. It will grow from $0.5 billion in 2025 to $0.55 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rising prevalence of peanut allergies in children, limited effectiveness of avoidance-only management, increased diagnosis of food allergies, strong reliance on epinephrine for emergency treatment, growing awareness among healthcare professionals.

The peanut allergy treatment market size is expected to see strong growth in the next few years. It will grow to $0.8 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to advancements in immunotherapy technologies, increasing approvals of disease-modifying treatments, rising demand for preventive allergy care, expansion of biologics targeting allergic pathways, growing investment in food allergy research. Major trends in the forecast period include rising adoption of oral immunotherapy for peanut desensitization, growing use of epicutaneous immunotherapy patches, increased integration of biologic therapies in allergy treatment, expansion of pediatric-focused peanut allergy treatments, greater emphasis on long-term allergy management solutions.

Investments in research and development for allergy treatments are poised to drive future growth in the peanut allergy treatment market. Research and development (R&D) investment involves the financial commitments made by companies, organizations, or governments to support innovation, product creation, and technological progress. Such investments in allergy treatments play a vital role in advancing therapies for peanut allergies. They enable the development of cutting-edge immunotherapies and desensitization methods designed to lessen allergic responses and enhance daily life for patients with peanut allergies. For example, in January 2024, the Victorian Government committed $12 million to Aravax, an Australian clinical-stage biotech firm, to accelerate global peanut allergy solutions. This contribution formed part of a larger $66 million funding round to advance Aravax's novel immunotherapy, PVX108. The project has gained Phase 2 trial approvals from the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), highlighting its broad potential for improving public health. Thus, R&D investments in allergy treatments are fueling expansion in the peanut allergy treatment market.

Major companies in the peanut allergy treatment sector are prioritizing biologic therapies, like anti-IgE monoclonal antibodies, to deliver more precise and potent options for managing peanut allergies. These aim to enhance patient results and overall well-being. Anti-IgE monoclonal antibodies work by specifically binding to and inactivating immunoglobulin E (IgE) antibodies within the body. For example, in February 2024, Novartis Pharmaceuticals Corporation - a pharmaceutical firm headquartered in Switzerland - gained FDA approval for Xolair (omalizumab). This drug helps lessen allergic responses, such as anaphylaxis, in individuals aged 1 and up who have IgE-mediated food allergies. The approval drew from results of the NIH-funded Phase III OUtMATCH trial, which demonstrated marked gains in food allergy tolerance for Xolair-treated patients versus those on placebo.

In September 2023, Stallergenes Greer International AG, a Switzerland-based supplier of allergen immunotherapy products, purchased the peanut allergy drug Palforzia from Nestlé S.A. for an undisclosed sum. This acquisition by Stallergenes Greer significantly broadens the company's anti-allergy offerings, enhancing its range of approved treatments for various allergies including grasses, mites, and trees. Nestlé S.A., a Switzerland-based company specializing in food, beverages, and peanut allergy medications, sold the asset.

Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc, Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd, Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

North America was the largest region in the peanut allergy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peanut allergy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the peanut allergy treatment market by increasing costs for imported biologics, medical-grade allergens, and delivery devices used in immunotherapy. These effects are most visible in hospital pharmacy channels and developed regions such as North America and Europe that rely on complex global supply chains. Higher costs have pressured pricing and slowed adoption in some markets. However, tariffs have also encouraged local manufacturing, domestic sourcing, and innovation in alternative delivery methods for allergy treatments.

The peanut allergy treatment market research report is one of a series of new reports that provides peanut allergy treatment market statistics, including peanut allergy treatment industry global market size, regional shares, competitors with a peanut allergy treatment market share, detailed peanut allergy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the peanut allergy treatment industry. This peanut allergy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peanut allergy treatment encompasses multiple medical strategies intended to control and lessen the intensity of reactions to peanuts. These methods include techniques like epicutaneous immunotherapy and biologic treatments, which focus on desensitizing patients to peanuts and reducing allergic responses.

The primary drug categories for treating peanut allergies include antihistamines, immunotherapies, epinephrine, and additional options. Antihistamines are medications that ease allergy symptoms by inhibiting histamine, a compound released by the immune system in response to allergic reactions. These drugs are delivered via injectables, oral forms, and other methods. Distribution occurs through retail pharmacies, hospital pharmacies, and other channels.

The peanut allergy treatment market consists of revenues earned by entities by providing services such as diagnostic testing, personalized treatment plans, oral immunotherapy sessions, patient education and counseling, monitoring of allergic reactions, and access to emergency care. The market value includes the value of related goods sold by the service provider or included within the service offering. The peanut allergy treatment market also includes sales of allergy drops, allergy tablets, and peanut allergen extract. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.